Tempest And Senlang To Collaborate To Develop Tempest’s Proprietary TPST-4003 Product Candidate, Beginning With IIT In China Evaluating TPST-4003 In ~10 Patients With MG Or MS; Expects First Patient Enrollment And Dosing To Occur In Q4 Of 2026
Tempest Therapeutics Inc TPST
$0.86
▼ -0.86%
($-0.01)
⬇️ Below Yest. Low
🎈 Low Float
🗓️ Earnings Next Week
Open
$0.88
Prev Close
$0.86
Day Range
$0.85 – $0.89
52W Range
$0.84 – $12.23
Market Cap
$13.68M
Beta
-1.64
EPS (TTM)
$-6.21
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2012-10-04 |
| Shares Out. | 15,980,000 |
| Website | tempesttx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 4 |
| Net Income | -$27.7M |
| Total Assets | $10.7M |
| Total Liabilities | $9.9M |
| Equity | $822,000 |
About Tempest Therapeutics Inc
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
Tempest Therapeutics Inc is a publicly traded company under the ticker symbol TPST on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)